PharmacoEconomics & Outcomes News 244 - 8 Jan 2000 Lansoprazole less costly than ranitidine in duodenal ulcer Lansoprazole is as effective as, but less costly than, ranitidine in the treatment of duodenal ulcer, say researchers in Slovenia. * This is the main finding of a decision-tree model of costs in a Slovenian context, based on clinical data from a 6-week randomised trial measuring ulcer-healing rates and symptom relief in 87 patients with duodenal ulcer. ** There were no significant between-group differences in clinical outcomes, say the researchers, who report that at 4 weeks both treatment groups had healing rates of about 95%. However, the modelled mean direct costs per patient (costs of medication, medical examinations and laboratory tests in 1997 US dollars) were $US931 for lansoprazole and $US1066 for ranitidine, a saving of $US135 in favour of lansoprazole. A sensitivity analysis which varied drug costs, other direct medical costs and healing rates, confirmed the robustness of the modelled findings. * Their study was funded by Krka, d.d., Slovenia. One of the researchers was employed by Merck and Co., Inc., US. ** 42 patients received lansoprazole 30 mg/day and 45 patients received ranitidine 300 mg/day for 2–4 weeks. Vreˇ cer M, et al. Modeling the cost-effectiveness of duodenal ulcer treatment with lansoprazole and ranitidine. Journal of Research in Pharmaceutical Economics 9: 43-61, No. 4, 1999 800806360 1 PharmacoEconomics & Outcomes News 8 Jan 2000 No. 244 1173-5503/10/0244-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Lansoprazole less costly than ranitidine in duodenal ulcer

Download PDF Report

Upload
lynhan
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 244 - 8 Jan 2000

Lansoprazole less costly thanranitidine in duodenal ulcer

Lansoprazole is as effective as, but less costly than,ranitidine in the treatment of duodenal ulcer, sayresearchers in Slovenia.* This is the main finding of adecision-tree model of costs in a Slovenian context,based on clinical data from a 6-week randomised trialmeasuring ulcer-healing rates and symptom relief in 87patients with duodenal ulcer.**

There were no significant between-group differencesin clinical outcomes, say the researchers, who reportthat at 4 weeks both treatment groups had healing ratesof about 95%. However, the modelled mean direct costsper patient (costs of medication, medical examinationsand laboratory tests in 1997 US dollars) were $US931for lansoprazole and $US1066 for ranitidine, a saving of$US135 in favour of lansoprazole.

A sensitivity analysis which varied drug costs, otherdirect medical costs and healing rates, confirmed therobustness of the modelled findings.* Their study was funded by Krka, d.d., Slovenia. One of theresearchers was employed by Merck and Co., Inc., US.** 42 patients received lansoprazole 30 mg/day and 45 patientsreceived ranitidine 300 mg/day for 2–4 weeks.

Vrecer M, et al. Modeling the cost-effectiveness of duodenal ulcer treatment withlansoprazole and ranitidine. Journal of Research in Pharmaceutical Economics 9:43-61, No. 4, 1999 800806360